However, TCR-based adoptive T-cell therapies still rely on appropriate target expression and recognition, and ultimately, the NY-ESO-1/LAGE-1a epitope–HLA complex may not be an optimal therapeutic target in lung cancer. This evidence concerns the gene CTAG2 and lung cancer.